Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo- and Active-Controlled Trial of JNJ-37822681 in Schizophrenia
2007-007083-22Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-37822681 in schizophrenia (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in total PANSS score at 6 weeks. Started Aug 2008; status: completed.
02
Drugs
JNJ-37822681
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-007083-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007083-22.